Amidinobenzylamine derivatives and their use as thrombin...

Details Amidinobenzylamine derivatives and their use as thrombin... Amidinobenzylamine derivatives and their use as thrombin...

2000-03-16

2003-07-29

McKane, Joseph K. (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C514S210170, C514S210180, C514S422000, C548S523000, C548S952000, C548S953000

Reexamination Certificate

active

06599894

ABSTRACT:

This application is a 371 of PCT/SE00/00052 filed Jan. 13, 2000.
FIELD OF THE INVENTION
This invention relates to novel pharmaceutically useful compounds, in particular compounds that are, or are prodrugs of, competitive inhibitors of trypsin-like serine proteases, especially thrombin, their use as medicaments, pharmaceutical compositions containing them and synthetic routes to their production.
BACKGROUND
Blood coagulation is the key process involved in both haemostasis (i.e. the prevention of blood loss from a damaged vessel) and thrombosis (i.e. the formation of a blood clot in a blood vessel, sometimes leading to vessel obstruction).
Coagulation is the result of a complex series of enzymatic reactions. One of the ultimate steps in this series of reactions is the conversion of the proenzyme prothrombin to the active enzyme thrombin.
Thrombin is known to play a central role in coagulation. It activates platelets, leading to platelet aggregation, converts fibrinogen into fibrin monomers, which polymerise spontaneously into fibrin polymers, and activates factor XIII, which in turn crosslinks the polymers to form insoluble fibrin. Furthermore, thrombin activates factor V and factor VIII leading to a “positive feedback” generation of thrombin from prothrombin.
By inhibiting the aggregation of platelets and the formation and crosslinking of fibrin, effective inhibitors of thrombin would be expected to exhibit antithrombotic activity. In addition, antithrombotic activity would be expected to be enhanced by effective inhibition of the positive feedback mechanism.
Further, it is known that administration of prodrugs of thrombin inhibitors may give rise to improvements m:
(a) certain pharmacokinetic properties after administration of; and
(b) the prevalence of certain side effects associated with, those inhibitors.
PRIOR ART
The early development of low molecular weight inhibitors of thrombin has been described by Claesson in Blood Coagul. Fibrinol. (1994) 5, 411.
Blombäck et al (in J. Clin. Lab. Invest. 24, suppl. 107, 59, (1969)) reported thrombin inhibitors based on the amino acid sequence situated around the cleavage site for the fibrinogen Aa chain. Of the amino acid sequences discussed, these authors suggested the tripeptide sequence Phe-Val-Arg (P9-P2-P1, hereinafter referred to as the P3-P2-P1 sequence) would be the most effective inhibitor.
Thrombin inhibitors based on dipeptidyl derivatives with an &agr;,&ohgr;-aminoalkyl guanidine in the P1-position are known from U.S. Pat. No. 4,346,078 and International Patent Application WO 93/11152. Similar, structurally related, dipeptidyl derivatives have also been reported. For example International Patent Application WO 94/29336 discloses compounds with, for example, aminomethyl benzamidines, cyclic aminoalkyl amidines and cyclic aminoalkyl guanidines in the P1-position (International Patent Application WO 97/23499 discloses prodrugs of certain of these compounds); European Patent Application 0 648 780, discloses compounds with, for example, cyclic aminoalkyl guanidines in the P1-position.
Thrombin inhibitors based on peptidyl derivatives, also having cyclic aminoalkyl guanidines (e.g. either 3- or 4-aminomethyl-1-amidino-piperidine) in the P1-position are known from European Patent Applications 0 468 231, 0 559 046 and 0 641 779.
Thrombin inhibitors based on tripeptidyl derivatives with arginine aldehyde in the P1-position were first disclosed in European Patent Application 0 185 390.
More recently, arginine aldehyde-based peptidyl derivatives, modified in the P3-position, have been reported. For example, International Patent Application WO 93/18060 discloses hydroxy acids, European Patent Application 0 526 877 des-amino acids, and European Patent Application 0 542 525 O-methyl mandelic acids in the P3-position.
Inhibitors of serine proteases (e.g. thrombin) based on electrophilic ketones in the P1-position are also known. For example, European Patent Application 0 195 212 discloses peptidyl &agr;-keto esters and amides, European Patent Application 0 362 002 fluoroalkylamide ketones, European Patent Application 0 364 344 &agr;,&bgr;,&dgr;-triketocompounds, and European Patent Application 0 530 167 &agr;-alkoxy ketone derivatives of arginine in the P1-position.
Other, structurally different, inhibitors of trypsin-like serine proteases based on C-terminal boronic acid derivatives of arginine and isothiouronium analogues thereof are known from European Patent Application 0 293 881.
More recently, thrombin inhibitors based on peptidyl derivatives have been disclosed in European Patent Application 0 669 317 and International Patent Applications WO 95/35309, WO 95/23609, WO 96/25426, WO 97/02284, WO 97/46577, WO 96/32110, WO 96/31504, WO 96/03374, WO 98/06740 and WO 97/49404.
However, there remains a need for effective inhibitors of trypsin-like serine proteases, such as thrombin. There is also a need for compounds which are both orally bioavailable and selective in inhibiting thrombin over other serine proteases, in particular those involved in haemostatis. Compounds which exhibit competitive inhibitory activity towards thrombin would be expected to be especially useful as anticoagulants and therefore in the therapeutic treatment of thrombosis and related disorders.
DISCLOSURE OF THE INVENTION
According to the invention there is provided a compound of formula I,
wherein
R
1
represents a N(R
5
)R
6
or a S(O)
m
R
7
substituent;
R
2
and R
3
independently represent an optional substituent selected from halo, C
1-4
alkyl or C
1-4
alkoxy (which latter two groups are optionally substituted by halo);
Y represents C
1-3
alkylene, optionally substituted by C
1-4
alkyl, methylene, ═O or hydroxy);
R
4
represents H, OH, OR
8a
, C(O)OR
8b
or R
8c
;
R
5
represents C
1-6
alkyl (optionally substituted by halo) or, together with
R
6
and the nitrogen atom to which R
5
and R
6
are attached, represents a 3- to 7-membered nitrogen containing ring, which ring optionally includes an oxygen atom and/or is optionally substituted with a ═O group;
R
6
represents C
1-6
alkyl (optionally substituted by halo), C(O)R
9
or, together with R
5
and the nitrogen atom to which R
5
and R
6
are attached, represents a 3- to 7-membered nitrogen-containing ring, which ring optionally includes an oxygen atom and/or is optionally substituted with a ═O group;
or the group N(R
5
)R
6
represents the structural fragment Ia,
R
6a
represents one or more optional substituents selected from halo, C
1-4
alkyl and C
1-4
alkoxy (which latter two groups are optionally substituted by halo);
X represents CH or N;
m represents 0, 1 or 2;
R
7
represents H, NH
2
or C
1-6
alkyl;
R
8a
and R
8b
independently represent C
1-10
alkyl, C
1-3
alkylphenyl or C
6-10
aryl, or R
8a
represents C(R
10a
)(R
10b
)OC(O)R
11
, C(R
10a
)(R
10b
)N(H)C(O)OR
12
or C(R
10a
)(R
10b
)OC(O)N(H)R
12
;
R
8c
represents C(R
10a
)(R
10b
)OC(O)R
11
, C(R
10a
)(R
10b
)N(H)C(O)OR
12
or C(R
10a
)(R
10b
)OC(O)N(H)R
12
;
R
10a
and R
10b
independently represent, at each occurrence, H or C
1-4
alkyl;
R
11
represents, at each occurrence, C
6-10
aryl, OR
12
or C
1-7
alkyl (which latter group is optionally substituted by a substituent selected from OH, CO
2
H and C
6-10
aryl);
R
12
represents, at each occurrence, C
6-10
aryl or C
1-6
alkyl (which latter group is optionally substituted by a substituent selected from OH, CO
2
H and C
6-10
aryl);
R
9
represents C
6-8
, alkyl, Het
1
, C
6-10
aryl or C
1-4
alkyl substituted by C
6-10
aryl; and
Het
1
represents a 4- to 12-membered heterocyclic ring, which ring contains one or more heteroatoms selected from oxygen, nitrogen and/or sulfur, and which ring may be fully saturated, partially saturated or aromatic and/or optionally monocyclic, bicyclic and/or benzo-fused; wherein each aryl/phenyl group and Het
1
group identified above is optionally substituted by one or more halo, C
1-4
alkyl and/or C
1-4
alkoxy groups (which latter two groups are themselves optionally substituted by one or more halo groups);
or a pharmaceuti

Affiliated with

Also associated with

Rating

Amidinobenzylamine derivatives and their use as thrombin... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Amidinobenzylamine derivatives and their use as thrombin..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Amidinobenzylamine derivatives and their use as thrombin... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3042776